(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
22 June 2006 (22.06.2006)

PCT

(10) International Publication Number
WO 2006/065780 A3

(51) International Patent Classification:
A61K 31/4745 (2006.01) *A61K 33/24* (2006.01)
A61K 31/427 (2006.01) *A61K 31/555* (2006.01)
A61K 31/337 (2006.01) *A61K 39/395* (2006.01)
A61K 31/53 (2006.01) *A61P 35/00* (2006.01)
A61K 31/282 (2006.01)

(21) International Application Number:
PCT/US2005/044993

(22) International Filing Date:
13 December 2005 (13.12.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/636,439 15 December 2004 (15.12.2004) US

(71) Applicant *(for all designated States except US)*: **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

(71) Applicant *(for AT only)*: **NOVARTIS PHARMA GMBH** [AT/AT]; Brunner Strasse 59, A-1230 Vienna (AT).

(71) Applicant *(for all designated States except US)*: **SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A** [IT/IT]; Viale Shakespeare 47, I-00144 Roma (IT).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **ZAKNOEN, Sara** [US/US]; 614 Madison Street, 2, Hoboken, New Jersey 07030 (US). **WOO, Margaret Ma** [US/US]; 609 Perlee Avenue, Raritan, New Jersey 08869 (US). **VERSACE, Richard William** [US/US]; 69 Townsend Road, Wanaque, New Jersey 07465 (US). **PISANO, Claudio** [IT/IT]; Via Cherubini, 60, I-04011 Aprilia (lt) (IT). **VESCI, Loredana** [IT/IT]; Via Orazio Console 29, I-00128 Roma (IT).

(74) Agent: **JACKSON, Oona A.**; NOVARTIS, Corporate Intellectual Property, One Health Plaza, Bldg. 104, East Hanover, NJ 07936 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:
— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

(88) Date of publication of the international search report:
17 August 2006

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: COMBINATIONS OF THERAPEUTIC AGENTS FOR TREATING CANCER

(57) Abstract: A combination therapy for treating patients suffering from proliferative diseases or diseases associated with persistent angiogenesis is disclosed. The patient is treated with a camptothecin derivative and one or more chemotherapeutic agents selected from a microtubule active agent; an alkylating agent; an anti-neoplastic anti-metabolite; a platin compound; a topoisomerase II inhibitor; a VEGF inhibitor; a tyrosine kinase inhibitor; an EGFR kinase inhibitor; an mTOR kinase inhibitor; an insulin-like growth factor I inhibitor; a Raf kinase inhibitor; a monoclonal antibody; a proteasome inhibitor; a HDAC inhibitor; and ionizing radiation.

WO 2006/065780 A3